[Risk of cancer and malignant transformation in hematology practice].
The cancer-morbidity growing year by year is in the focus of investigations all over the world. Beyond inherited factors this could be related to the environmental harm posed to men day by day. In this study questions will be discussed especially concerning carcinogenicity of cytostatic therapy being paradoxically a part of this process. The newly recognised relation between the hemochromatosis gene mutation and myelodysplasia opens new avenues in the understanding process of the pathomechanism of myelodysplastic syndromes. Deliberation tissues from iron of oxidative potential may reduce transfusion need and postpone blastic transformation. The aim of the study is to call for attention on the group of multiple myeloma patients and their first degree relatives having high risk for cancer emphasizing the importance of their follow up.
Várkonyi
Judit
J
Altalános Orvostudományi Kar, III. sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest.
D000970:Antineoplastic Agents / Q000009:adverse effects; D002471:Cell Transformation, Neoplastic; D020022:Genetic Predisposition to Disease; D019337:Hematologic Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics*; D006432:Hemochromatosis / Q000235:genetics; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D015994:Incidence; D007938:Leukemia / Q000139:chemically induced; D009101:Multiple Myeloma / Q000235:genetics; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics; D018570:Risk Assessment; D012307:Risk Factors
D000970:Antineoplastic Agents